Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial
BACKGROUND: Sentinel lymph node biopsy is standard for staging clinically node-negative (cN0) breast cancer, but the dual tracer gold-standard radioisotope-blue dye technique is unavailable in resource-limited settings. Fluorescein, an inexpensive, safe, visible-light tracer, has no randomized data after neoadjuvant chemotherapy (NACT). We compared fluorescein-methylene blue with methylene blue alone for sentinel lymph node biopsy in post-NACT cN0 patients and, secondarily, assessed the accuracy of axillary ultrasound. METHODS: In this randomized pilot feasibility trial, post-NACT cN0 breast cancer patients were randomized 1:1 to fluorescein-methylene blue (FlaB) or methylene blue alone after dye allergy testing. All patients underwent completion axillary lymph node dissection as the reference standard. Identification rate and false-negative rate were estimated with 95% confidence intervals. RESULTS: Of 136 patients who received NACT, 62 (45.6%) had a clinical complete nodal response and were recruited; 2 (3.2%) were excluded for methylene blue allergy, leaving 30 randomized per group, with all 60 completing the protocol. IR: 93.3% (28/30; 95% CI, 78.7-98.1) with FlaB versus 83.3% (25/30; 95% CI, 66.4-92.7) with methylene blue alone (difference, 10.0 percentage points; p = 0.23). FNR: 11.1% (2/18; 95% CI, 3.1-32.8) versus 12.5% (2/16; 95% CI, 3.5-36.0; p = 0.87). On secondary analysis, axillary ultrasound was normal in 30 of 62 patients (48.4%) and suspicious in 32 (51.6%); against final pathology, its sensitivity was 80.6%, and its negative predictive value was 76.7%; 7 of the 36 node-positive patients (19.4%) had a sonographically normal axilla. No dye-related adverse events occurred. CONCLUSION: FlaB achieved an identification rate above the 90% benchmark and a false-negative rate comparable to radioisotope-based dual-tracer series. Axillary ultrasound did not reliably exclude residual nodal disease (negative predictive value 76.7%) and cannot replace pathological nodal staging after NACT. Fluorescein-methylene blue is a safe, radioisotope-free dual-tracer strategy for SLNB in resource-limited settings.
Authors
- Dharma Ram Poonia (ORCID: https://orcid.org/0000-0003-0224-5012)
- Sanjeev Misra (ORCID: https://orcid.org/0000-0002-0641-0946)
- Rahul Yadav (ORCID: https://orcid.org/0000-0003-0045-4814)
- Puneet Pareek (ORCID: https://orcid.org/0000-0002-6055-9872)
- Byshetty Rajendar
- Jeewan Ram Vishnoi (ORCID: https://orcid.org/0000-0003-1484-8929)
- Poonam Abhay Elhence (ORCID: https://orcid.org/0000-0002-4660-389X)
- Nivedita Sharma (ORCID: https://orcid.org/0000-0002-0754-6300)
- Taruna Yadav (ORCID: https://orcid.org/0000-0002-3644-6093)
Institutions
- All India Institute of Medical Sciences Jodhpur (IN)
- CARE Hospitals (IN)
- King George's Medical University (IN)
Publication Details
- Journal
- World Journal of Surgery
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1002/wjs.70696
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00